Featured Research

from universities, journals, and other organizations

Study questions recommendation to discontinue LABA therapy in asthma patients

Date:
August 27, 2012
Source:
Creighton University
Summary:
An extensive literature review and analysis of five clinical trials suggests that discontinuing long-acting β2-agonist (LABA) therapy in adults and older children who have asthma that is controlled with a combination of inhaled corticosteroids and LABAs may be associated with increased asthma-related impairment, according to a new report.

An extensive literature review and analysis of five clinical trials suggests that discontinuing long-acting β2-agonist (LABA) therapy in adults and older children who have asthma that is controlled with a combination of inhaled corticosteroids and LABAs may be associated with increased asthma-related impairment, according to a report published in Online First by Archives of Internal Medicine, a JAMA Network publication released Aug. 27.

Thomas Casale, M.D., professor of medicine and chief of Allergy/Immunology, Creighton University, served as a primary author of the paper. Currently the U.S. Food and Drug Administration recommends that once asthma is controlled, LABA be withdrawn because of safety concerns.

"Our evidence suggests that such an action could result in increased asthma-associated impairment. At a minimum there is a lack of studies evaluating the issue," said Casale.

A LABA step-off regimen appeared to increase asthma impairment, with worse Asthma Quality of Life Questionnaire scores; worse Asthma Control Questionnaire scores; and fewer symptom-free days, according to study results.

Authors recognize that there is a FDA mandate for LABA safety studies by manufacturers of these agents but results won't be available for about five years.

"Our analysis supports the positive effects of LABAs for achieving and maintaining asthma control," Casale added.


Story Source:

The above story is based on materials provided by Creighton University. Note: Materials may be edited for content and length.


Journal Reference:

  1. Jan L. Brozek et al. Long-Acting β2-Agonist Step-off in Patients With Controlled Asthma. Arch Intern Med., August 27, 2012 DOI: 10.1001/archinternmed.2012.3250

Cite This Page:

Creighton University. "Study questions recommendation to discontinue LABA therapy in asthma patients." ScienceDaily. ScienceDaily, 27 August 2012. <www.sciencedaily.com/releases/2012/08/120827151623.htm>.
Creighton University. (2012, August 27). Study questions recommendation to discontinue LABA therapy in asthma patients. ScienceDaily. Retrieved September 1, 2014 from www.sciencedaily.com/releases/2012/08/120827151623.htm
Creighton University. "Study questions recommendation to discontinue LABA therapy in asthma patients." ScienceDaily. www.sciencedaily.com/releases/2012/08/120827151623.htm (accessed September 1, 2014).

Share This




More Health & Medicine News

Monday, September 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

We've Got Mites Living In Our Faces And So Do You

We've Got Mites Living In Our Faces And So Do You

Newsy (Aug. 30, 2014) A new study suggests 100 percent of adult humans (those over 18 years of age) have Demodex mites living in their faces. Video provided by Newsy
Powered by NewsLook.com
Liberia Continues Fight Against Ebola

Liberia Continues Fight Against Ebola

AFP (Aug. 30, 2014) Authorities in Liberia try to stem the spread of the Ebola epidemic by raising awareness and setting up sanitation units for people to wash their hands. Duration: 00:41 Video provided by AFP
Powered by NewsLook.com
California Passes 'yes-Means-Yes' Campus Sexual Assault Bill

California Passes 'yes-Means-Yes' Campus Sexual Assault Bill

Reuters - US Online Video (Aug. 30, 2014) California lawmakers pass a bill requiring universities to adopt "affirmative consent" language in their definitions of consensual sex, part of a nationwide drive to curb sexual assault on campuses. Linda So reports. Video provided by Reuters
Powered by NewsLook.com
New Drug Could Reduce Cardiovascular Deaths

New Drug Could Reduce Cardiovascular Deaths

Newsy (Aug. 30, 2014) The new drug from Novartis could reduce cardiovascular deaths by 20 percent compared to other similar drugs. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins